Live Breaking News & Updates on Marshall Urist

Stay updated with breaking news from Marshall urist. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Royalty Pharma : Vorasidenib Transaction Call Transcript

REFINITIV STREETEVENTS

EDITED TRANSCRIPT

RPRX.OQ - Royalty Pharma PLC To Host Investor Call

. ....

United-states , America , Michael-difiore-evercore , Terence-flynn-morgan-stanley , Michael-difiore , Terry-coyne , Pablo-legorreta , Geoff-meacham , Terence-flynn , George-grofik , Marshall-urist , Research-investments

Royalty Pharma : BofA Health Care Conference Transcript

REFINITIV STREETEVENTS

EDITED TRANSCRIPT

RPRX.OQ - Royalty Pharma PLC at Bank of America Healthcare Conference
. ....

United-states , America , Terry-coyne , Geoffrey-meacham-bof , Terrance-coyne , Marshall-urist , Geoffrey-meacham , Geoff-meacham , Research-investments , Royalty-pharma , Research-division , Head-of-research

Royalty Pharma plc (NASDAQ:RPRX) Q1 2024 Earnings Call Transcript

Royalty Pharma plc (NASDAQ:RPRX) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

United-states , America , Terry-coyne , Chris-schott , Geoff-meacham , Terrance-coyne , Chris-shibutani , Marshall-urist , Pablo-legorreta , George-grofik , Repros-therapeutics-inc , Goldman-sachs

Royalty Pharma plc (NASDAQ:RPRX) Q3 2023 Earnings Call Transcript

Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma Third Quarter 2023 Earnings Conference Call. ....

Chris-schott , Stephen-scala , George-grofik , Christopher-schott , Andrew-baum , Marshall-urist , Pablo-legorreta , Terrance-coyne , Terry-coyne , Repros-therapeutics-inc , Nasdaq , Life-sciences

Royalty Pharma (NASDAQ:RPRX) Cut to "Hold" at StockNews.com

StockNews.com cut shares of Royalty Pharma (NASDAQ:RPRX – Get Rating) from a buy rating to a hold rating in a research note published on Thursday morning. RPRX has been the subject of several other reports. UBS Group dropped their price target on Royalty Pharma from $51.00 to $48.00 and set a buy rating for the […] ....

United-states , Marshall-urist , Roryb-riggs , Royalty-pharma-company-profile , Blackrock-inc , Morgan-stanley , Securities-exchange-commission , Jpmorgan-chase-co , Baillie-gifford-co , Vanguard-group-inc , Royalty-pharma , Get-rating